Literature DB >> 15678790

Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women.

Pilar Orozco1.   

Abstract

Epidemiological studies have reported that women with osteoporosis present an increased risk of cardiovascular events and that lipid lowering therapy (statins) could be associated with a decreased risk of fracture. We investigated whether women with atherogenic lipid profile have lower lumbar and femoral bone mineral density (BMD) and higher prevalence of osteopenia than those with normal lipid levels. The study included 52 overweight early postmenopausal women, with no history of hormone replacement therapy, or any current or past pathology or treatment that could alter bone or lipid metabolism. Atherogenic lipid profile or hyperlipidemia was defined as hypercholesterolemia (> or = 240 mg/dl) or high low-density lipoprotein cholesterol (high-LDLc > or = 160 mg/dl) or high lipoprotein (a) [high-Lp (a) > or =25 mg/dl], and low-BMD as t-score <-1 SD at lumbar o femoral site. The results show that women with hyperlipidemia had lower mean-adjusted BMD (mean+/-SEM) at lumbar (0.865+/-0.020 vs. 0.958+/-0.028 g/cm2, p = 0.007) and femoral neck (0.712+/-0.015 vs. 0.796+/-0.021, p = 0.004 g/cm2) than those with normal lipid levels. Hypercholesterolemia group had higher prevalence of low-BMD at lumbar spine (82.6% vs. 55.2%, p = 0.04, OR: 3.8; 95% CI: 1.04-14.2) and femoral neck (65.2% vs. 37.9%, p = 0.05, OR: 3.1; 95% CI: 0.98-9.6). The high-LDLc group had also higher prevalence low-BMD at femoral neck (75% vs. 39%, p = 0.01, OR: 4.7; 95% CI: 1.26-17.5), and the high-Lp (a) group at lumbar spine (87% vs. 51.7% p = 0.007, OR: 6.2; 95% CI: 1.5-25.6). Women with hyperlipidemia had higher prevalence of low BMD at lumbar spine (81.8% vs. 42.1%, p = 0.003, OR: 6.2; 95% CI: 1.7-22) and femoral neck (60.6% vs. 31.6%, p = 0.04, OR: 3.3; 95% CI: 1.01-11.0). In conclusion, early postmenopausal women with atherogenic lipid profile, defined as cholesterol > or =240 mg/dl or LDLc > or = 160 mg/dl or Lp(a) > or = 25 mg/dl have lower lumbar and femoral BMD and have an increased risk of osteopenia than those with normal lipid profile, suggesting that hyperlipidemia could be associated with osteoporosis and bone status should be evaluated in women with hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15678790     DOI: 10.1007/s10654-004-1706-8

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  34 in total

1.  Characterization of perimenopausal bone loss: a prospective study.

Authors:  R Recker; J Lappe; K Davies; R Heaney
Journal:  J Bone Miner Res       Date:  2000-10       Impact factor: 6.741

2.  Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.

Authors:  A Decensi; C Robertson; B Ballardini; D Paggi; A Guerrieri-Gonzaga; B Bonanni; L Manetti; H Johansson; A Barreca; D Bettega; A Costa
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

3.  Lipoprotein (a) is associated with endothelial function in healthy postmenopausal women.

Authors:  H W Wilmink; M J de Kleijn; M L Bots; A A Bak; Y T van der Schouw; S Engelen; J Planellas; J Banga; D E Grobbee
Journal:  Atherosclerosis       Date:  2000-11       Impact factor: 5.162

4.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women.

Authors:  K A Chan; S E Andrade; M Boles; D S Buist; G A Chase; J G Donahue; M J Goodman; J H Gurwitz; A Z LaCroix; R Platt
Journal:  Lancet       Date:  2000-06-24       Impact factor: 79.321

5.  Does serum cholesterol contribute to vertebral bone loss in postmenopausal women?

Authors:  L B Tankó; Y Z Bagger; S B Nielsen; C Christiansen
Journal:  Bone       Date:  2003-01       Impact factor: 4.398

6.  Impact of glycemic control on serum lipoprotein (a) in Arab children with type 1 diabetes.

Authors:  M Alsaeid; M Qabazard; A Shaltout; P N Sharma
Journal:  Pediatr Int       Date:  2001-06       Impact factor: 1.524

7.  Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

Authors:  I F Godsland
Journal:  Fertil Steril       Date:  2001-05       Impact factor: 7.329

8.  Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women.

Authors:  E I Barengolts; M Berman; S C Kukreja; T Kouznetsova; C Lin; E V Chomka
Journal:  Calcif Tissue Int       Date:  1998-03       Impact factor: 4.333

9.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study.

Authors:  Julie A Pasco; Mark A Kotowicz; Margaret J Henry; Kerrie M Sanders; Geoffrey C Nicholson
Journal:  Arch Intern Med       Date:  2002-03-11

10.  [An exploratory study of the association between lipid profile and bone mineral density in menopausal women in a Campinas reference hospital].

Authors:  S F Zabaglia; A O Pedro; A M Pinto Neto; T Guarisi; L H Paiva; E Lane
Journal:  Cad Saude Publica       Date:  1998 Oct-Dec       Impact factor: 1.632

View more
  37 in total

1.  The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors.

Authors:  Erik R Nelson; Carolyn D DuSell; Xiaojuan Wang; Matthew K Howe; Glenda Evans; Ryan D Michalek; Michihisa Umetani; Jeffrey C Rathmell; Sundeep Khosla; Diane Gesty-Palmer; Donald P McDonnell
Journal:  Endocrinology       Date:  2011-09-20       Impact factor: 4.736

2.  Hypercholesterolemia promotes an osteoporotic phenotype.

Authors:  Kristine Pelton; Jaclynn Krieder; Danese Joiner; Michael R Freeman; Steven A Goldstein; Keith R Solomon
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

3.  New Clues that May Link Osteoporosis to the Circulating Lipid Profile.

Authors:  Catalina Poiana; Valentin Radoi; Mara Carsote; John P Bilezikian
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

Review 4.  The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review.

Authors:  Christos G Mihos; Rosa T Artola; Orlando Santana
Journal:  Rheumatol Int       Date:  2011-07-31       Impact factor: 2.631

Review 5.  27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.

Authors:  Sisi He; Erik R Nelson
Journal:  Maturitas       Date:  2017-07-31       Impact factor: 4.342

6.  Multisystem dysregulation and bone strength: findings from the study of midlife in the United States.

Authors:  Takahiro Mori; Arun S Karlamangla; Sharon Stein Merkin; Carolyn J Crandall; Neil Binkley; Gail A Greendale; Teresa E Seeman
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

7.  Hyperlipidemia compromises homing efficiency of systemically transplanted BMSCs and inhibits bone regeneration.

Authors:  Quan-Chen Xu; Peng-Jie Hao; Xin-Bo Yu; Shu-Lan Chen; Mei-Jiao Yu; Jin Zhang; Pi-Shan Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  Bone mineral density in prediabetic men.

Authors:  Ju Hee Lee; Yun Hyeong Lee; Kyoung Hye Jung; Min Kyeong Kim; Hye Won Jang; Tae Kyun Kim; Hyun Jin Kim; Young Suk Jo; Minho Shong; Tae Yong Lee; Bon Jeong Ku
Journal:  Korean Diabetes J       Date:  2010-10-31

9.  Association of lipid parameters and insulin resistance with bone health in South Korean adolescents.

Authors:  S-W Park; G-E Nam; D-W Jung; S-J Yoon; K Han; Y-G Park; J-S Choi; J-E Lee; J-E Sang; Y-J Yoon; D-H Kim
Journal:  Osteoporos Int       Date:  2015-09-02       Impact factor: 4.507

10.  From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).

Authors:  Suzanne E Wardell; Erik R Nelson; Donald P McDonnell
Journal:  Steroids       Date:  2014-07-30       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.